Menu Back to Biosimilars-Conference


Conference | September 20-21

At the DIA Biosimilars Conference 2022, manufacturers, regulators, payers, prescribers, and patients will convene to discuss factors that influence biosimilar access and development and share perspectives on what success and progress looks like to provide cost-saving options for providers and patients in need

Attendees will apply practical solutions and forward-thinking learnings from around the world, to help build strategies for growth of the biosimilar’s market

  • Event Goals and Offerings

    • Increase understanding of access to safe, effective, and cost-effective biological treatment options
    • Collaborate with professionals in science, regulation, R&D, and more, to address barriers in biosimilar development
    • Eliminate misinformation that delays policies to increase patient access
    • Streamline global and regional goals with all stakeholder perspectives
    • View Agenda

  • Why You Can’t Miss It

    • Increase potential of and access to the biosimilar’s market
    • Meet and network with professionals involved in ongoing regulatory, manufacturing, pricing, and educational challenges
    • Discuss influencing factors of biosimilar development by including stakeholders embedded in this space
    • Apply the newest thinking and global learnings for strategic growth in biosimilar product development
    • Incorporate viewpoints of manufacturers, regulators, payers, prescribers, and patients altogether
    • Register Now

  • Learning Objectives

    At the conclusion of this activity, participants should be able to:

    • Discuss current developments in regulatory and scientific issues and their impact on development, manufacturing, access, and uptake of biosimilars and interchangeable products
    • Discuss imperative and progress in streamlining biosimilar development
    • Describe the impact of the approval of the first interchangeable biosimilar from a scientific and policy perspective
    • Examine current prescriber and patient confidence and patterns of biosimilar use, and education efforts that have been successful in increasing literacy on these products
    • Describe relevant international developments influencing patterns of biosimilar uptake globally
    • Describe the status of biosimilar product development, availability, and uptake in the US

  • Meeting Designed For

    • Biosimilar/Biologic/Biomedical R&D
    • Chemistry, Manufacturing and Controls
    • Regulatory Affairs
    • (Non)Clinical Research
    • Business & Data Development
    • Marketing/Medical Communications
    • Patient Advocacy/Patient Support Programs
    • Health Education & Provision
    • Quality Analysis & Management
    • Register Now

Program Committee

  • Leah  Christl, PhD
    Leah Christl, PhD Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy
    Amgen, United States
  • Tiffany  Fletcher, MA
    Tiffany Fletcher, MA Head of Global Access Policy
    Viatris, United States
  • Denis  Arsenault, MA
    Denis Arsenault, MA Manager, Policy Development
    Health Canada, Canada
  • Mauricio  Ede, MD, PhD
    Mauricio Ede, MD, PhD Chief Medical & Scientific Officer
    Sandoz Canada Inc., Canada
  • Stanton  Mehr
    Stanton Mehr Director of Content
    Biosimilars Review and Report, United States
  • Juliana Marguerite Reed, MS
    Juliana Marguerite Reed, MS Executive Director
    The Biosimilars Forum, United States
  • Stacey  Ricci, DrSc
    Stacey Ricci, DrSc Director, Scientific Review Staff, OTBB, OND, CDER
    FDA, United States
  • Cecil J. Nick, MS
    Cecil J. Nick, MS FTOPRA, Vice President (Technical)
    Parexel Consulting, United Kingdom
Load More

Digital Learning Catalog

DIA Learning: eLearning Soultions